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Case report Primary nasopharyngeal Hodgkin's disease: case 
report and literature review
Youssef Bensouda*1, Kawtar El Hassani1, Nabil Ismaili1, Issam Lalya1, Saber Boutayeb1, Nourredine Benjaafar2, 
Brahim Khalil El Gueddari2 and Hassan Errihani1
Abstract
Introduction: Primary Hodgkin's disease of the nasopharynx is a rare and uncommon event. It has a relatively 
favorable prognosis and represents less than 1% of all documented cases of Hodgkin's disease.
Case presentation: A 40-year-old Arabic man presented initially with bilateral nasal obstruction, which was then 
followed by a significant involvement of his bilateral cervical lymph nodes. His nasopharyngeal biopsy together with 
immunohistochemistry analysis showed negative expressions of CD15, CD20 and CD3, but positive expressions of 
CD30 and epithelial membrane antigen. This confirmed the diagnosis of nasopharyngeal Hodgkin's disease of a mixed 
cellularity subtype. The disease was at stage IIEA. Our patient received four cycles of chemotherapy, which yielded a 
75% response. This was followed by irradiation of his Waldeyer's ring and supraclavicular lymph nodes. He remains in 
good local control after 30 months of follow-up.
Conclusion: The literature review and our case report discuss the optimal management of this rare and atypical 
localization of Hodgkin's disease, which should be differentiated from lymphoproliferations associated with Epstein-
Barr virus and non-Hodgkin's lymphoma.
Introduction
The lymphoid tissues of Waldeyer's ring, including the
nasopharynx, are rarely involved in Hodgkin's disease
(HD). Primary nasopharyngeal presentation is extremely
rare, occurring in less than 1% of all reported cases of HD.
With appropriate treatment the prognosis for this partic-
ular type of HD is favorable. Most documented cases of
HD are either stage I or II.
We present the case of a patient with primary nasopha-
ryngeal HD which was managed by a combination of
sequential chemotherapy and radiotherapy. This treat-
ment yielded optimal local control after 30 months of fol-
low-up.
We reviewed the literature and considered questions
about the rarity of this case, the optimal management of
its atypical localization, and the need for immunohis-
tochemistry (IHC) analysis in differentiating HD from
non-Hodgkin's lymphoma (NHL) and lymphoprolifera-
tions associated with Epstein-Barr virus (EBV).
Case presentation
In October 2005, a 40-year-old Arabic man with a long
history of smoking presented at the National Institute of
Oncology for a consultation. Over a period of one year, he
had developed progressive bilateral nasal obstruction
with a secondary cervical left mass that was associated
with headaches and hypoacusis. No fever, pruritus, sweat
or weight loss was noted. His full blood count, biochemi-
cal tests and erythrocyte sedimentation rate were all nor-
mal. A clinical examination of our patient found his
cervical left lymph nodes measured 8 × 5 cm and right
submaxillary lymph nodes measured 5 × 4 cm.
A computed tomography (CT) scan of his nasopharynx
and nasofibroscopy revealed a posterolateral nasopha-
ryngeal mass and bilateral cervical lymph nodes (Figures
1 and 2). A nasopharyngeal biopsy and IHC analysis con-
firmed the diagnosis of HD of a mixed cellularity type
(CD30+, epithelial membrane antigen positive [EMA+],
CD15-, CD20-, CD3- and cytokeratin).
The results of his bone marrow biopsy, and chest, abdo-
men and pelvic CT scans were all normal. His disease was
staged at IIEA according to the Ann Arbor classification
system.
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Our patient was then treated using four cycles of che-
motherapy every three weeks with an alternating regimen
of cyclophosphamide, Oncovin (vincristine), predniso-
lone (COP) and Adriamycin (doxorubicin), bleomycin,
vinblastine (ABV) (day one: COP; day eight: ABV). His
radiological evaluation after the fourth cycle showed a
complete resolution of the nasopharyngeal mass and a
75% response in his cervical nodes (Figure 3). The treat-
ment was then completed by irradiation of his Waldeyer's
ring and cervical lymph nodes with a total dosage of 36
Gy. Our patient remains in good local control after 30
months of follow-up.
Discussion
W e  r e p o r t  t h e  r a r e  c a s e  o f  a  p a t i e n t  w i t h  p r i m a r y
nasopharyngeal HD which was successfully managed by a
sequential combination of chemotherapy and radiother-
apy.
Hodgkin's disease localized in the head and neck
regions is mostly seen in the nodal tissues. Extranodal
involvement is rarely reported. According to Eavey and
Goodman, only two cases of nasopharyngeal HD have
been identified in a study of 500 cases of HD localized in
the head and neck regions [1].
Primary nasopharyngeal presentation is exceptional in
HD cases, as it occurs in less than 1% of all reported HD
Figure 1 Computed tomography scan before treatment. Left na-
sopharyngeal mass involving the parapharyngeal space but without 
extracranial or bone involvement.
Figure 2 Computed tomography scan before treatment. Left na-
sopharyngeal mass involving the parapharyngeal space but without 
extracranial or bone involvement.
Figure 3 Computed tomography scan after chemotherapy. Com-
plete regression of nasopharyngeal mass with cervical necrosis lymph 
nodes.Bensouda et al. Journal of Medical Case Reports 2010, 4:116
http://www.jmedicalcasereports.com/content/4/1/116
Page 3 of 5
localizations. In another case report, Anselmo et al.
reported only seven cases (0.32%) of nasopharyngeal HD
in a large retrospective study involving 2150 cases of HD
documented over a period of 24 years [2].
Compared with HD, NHLs are more frequently local-
ized in the head and neck regions. A retrospective review
of 311 head and neck lymphomas reported only three
cases (4%) of HD whereas NHL cases were 24% of the
total [3]. Fewer than 90 cases of HD with nasopharyngeal
involvement have been reported in the literature world-
wide; but only 20 of these cases primarily involved the
nasopharyngeal region [2,4-12] (Table 1).
Hodgkin's disease is predominantly seen in male
patients, and mixed cellularity is its most frequent histo-
logical subtype [2,12]. Because EBV was found in the
majority of cases reported, nasopharyngeal HD should be
differentiated from lymphoproliferations associated with
EBV.
Before IHC analyses became widely available, some
authors speculated that nasopharyngeal HD localization
might have been under-diagnosed [1,12]; but judging
from its continued rarity, it appears that this claim is
false.
To confirm a diagnosis of nasopaharyngeal HD, an IHC
analysis is necessary. As found in the majority of cases,
Reed-Stenberg cells with positive expressions of CD30
and/or CD15, and negative expressions of CD20, CD3
and CD4, corroborate the diagnosis (Table 2).
The treatment of nasopharyngeal HD should be similar
to that used in other HD localizations, which involve a
sequential combination of chemotherapy and radiother-
apy . W e believe that four cycles of a chemotherapeutic
regimen (Adriamycin [doxorubicin], bleomycin, vinblas-
tine, dacarbazine [ABVD] polychemotherapy) is the
appropriate standard regimen; and involved field radio-
therapy with target volume given as an intermediate dos-
age (25 to 40 Gy) targeting the Waldeyer's ring and
cervical lymph nodes should be the first line of treatment
for patients with nasopharyngeal HD. Furthermore,
exclusive irradiation should be proposed for isolated
Table 1: Case reports of primary nasopharyngeal Hodgkin's disease in the literature: patient characteristics.
Author Age Sex Stage Treatment Response DFS
Our Case 40 M IIE Aa CT 4 × COP/ABVTRT PR 75% 30 m
Atasoy 2006 [4] 45 F IE A RT CR 26 m
Kochbati 2006 [5]
Case 1 41 M IE Aa RT CR 3 y
Case 2 36 M IIE Aa CT 3 × ABVDTRT PR 90% 6 m
Case 3 77 F IIE Aa CT 3 × ABVDTRT PR nv
Hollander 2004 [6] 36 M IIE CT 6 × ABVDTRT CR 6 m
Takashima 2003 [7] 46 M IE A CT 3 × ABVDTRT CR 6 m
Anselmo 2002 [2]
Case 1 44 M IIE A RT (mantle) CR 24 y
Case 2 47 M IIE A CT 2 × ABVDTRT CR 6 y
Case 3 40 M IIE A CT 4 × ABVDTRT CR 8 y
Case 4 34 M IE A CR 6 y
Case 5 25 M IIE A CT 2 × ABVDTRT CR 6 y
Case 6 43 M IIE A CT 4 × ABVDTRT CR 3 m
Case 7 29 M IIE A CT 2 × ABVDTRT CR 1 m
Herrmann 2002 [8] 43 F IE A Compl resection CR 14 m
Folz 2000 [9] 45 M IIE A Partial resection PR nv
Molony 1998 [10] 46 M IIE Aa CT 3 × CVPPTRT CR nv
Daniel 1988 [11] 23 M IE Adenoidectomy + RT CR 7 y
O'Reilly 1987 [12] 62 M IE A RT CR 14 m
DFS: disease-free survival, M: male, F: female, CT: chemotherapy, RT: radiotherapy, ABVD: Adriamycin (doxorubicin), bleomycin, vinblastine, 
dacarbazine, COP: cyclophosphamide, Oncovin (vincristine), prednisolone, Compl: complete, CR: complete response, PR: partial response, m: 
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cases of nasopharyngeal HD that do not involve the cervi-
cal lymph nodes and do not present with general symp-
toms.
Conclusion
From data gathered through our case and literature
review, we conclude that nasopharyngeal HD is an atypi-
cal and rare localization. The majority of cases reported
are localized at stage I or II; our patient was diagnosed at
stage IIEA.
The optimal management of primary nasopharyngeal
HD is still unclear. Its treatment, first with chemotherapy
followed by involved field irradiation, appears to be an
adapted therapy, especially when cervical lymph nodes
are involved. This combined treatment is associated with
the long-term cessation of the disease.
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Table 2: Case reports of primary nasopharyngeal Hodgkin's disease in the literature: subtype and immunohistochemistry 
pattern.
Author Subtype HD CD15 CD30 EMA LMP1 CD3 CD20 CD45
Our case MC - + + - -
A t a s o y  2 0 0 6  [ 4 ] M C + + ----
Kochbati 2006 [5]
Case 1 MC - + + - -
Case 2 MC +
C a s e  3 M C ++- - +
Hollander 2004 [6] MC + + +





Case 4 LP + + - -
Case 5 Interfollicular
Case 6 NS +/- +
Case 7 LP + +
Herrmann 2002 [8] NS + +
Folz 2000 [9] LP + +
Molony 1998 [10] Classical + + +/- - -
Daniel 1988 [11] MC
O'Reilly 1987 [12] LP
EMA: epithelial membrane antigen, MC: mixed cellularity, NS: nodular sclerosis, LP: lymphocyte predominance.Bensouda et al. Journal of Medical Case Reports 2010, 4:116
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